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Abstract
Background: The purpose of this study was to retrospectively evaluate our experience with
gallbladder cancer since the establishment of a tumour registry in our institute.
Methods: Between 1975 and 1998, 23 consecutive patients with gallbladder cancer were identified
using the tumour registry database. There were 18 females (78%) and 5 (22%) males. The mean age
at diagnosis was 70.6 (range 42–85) years. The diagnosis was achieved either intra-operatively or
following the histological analysis of the gallbladder (n = 17), following gallbladder or liver biopsy (n
= 4) or at autopsy (n = 2). Presenting symptoms included upper abdominal pain, weight loss, nausea,
vomiting, fever, painless jaundice, hepatomegaly, upper abdominal mass, upper abdominal
tenderness, and gastrointestinal haemorrhage.
Results:  Histological examination revealed 20 adenocarcinomas (87%), 2 squamous cell
carcinomas (9%) and one spindle cell sarcoma (4%). At presentation, 14 (61%) gallbladder cancers
were stage IV, 5 (22%) were stage III and 4 (17%) were stage II. Kaplan Meier analysis revealed a
mean survival of 3.2, 7.8 and 8.2 months for stage IV, III, and II disease respectively. Out of 14
patients with stage IV disease, 8 patients received adjuvant chemotherapy and survived for 4.6
months whereas six patients who did not receive adjuvant chemotherapy survived for 1.3 months.
This difference was statistically significant (p = 0.04).
Conclusion: The majority of patients with gallbladder cancer presented with advanced stage
disease (stage IV) which carries a dismal prognosis. Patients who received chemotherapy with stage
IV disease, however, did better than those who did not, but this is probably a reflection of patient
selection.
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Background
Carcinoma of the gallbladder is a rare malignancy
accounting for approximately 7,100 new cases and 3,500
deaths per annum in the US. It is the most common bil-
iary tract malignancy and the fifth most frequent gastroin-
testinal malignancy [1]. Its clinical presentation is non-
specific and the majority of patients have advanced dis-
ease at presentation. The aim of this article is to review our
experience of gallbladder carcinoma since the establish-
ment of a tumour registry in our institute.
Methods
Between 1975 and 1998, 23 consecutive patients with his-
tological proven gallbladder cancer treated at St. Joseph's
Hospital, Omaha, Nebraska were identified using the
tumour registry database. There were 18 females (78%)
and 5 (22%) males. All but one patient were Caucasian.
The mean age at diagnosis was 70.6  (range 42–85) years.
In 17 (74%) patients the cancer was diagnosed either
intra-operatively or following the histological analysis of
the gallbladder. In 4 patients, due to the extensive nature
of the disease, the diagnosis was confirmed following gall-
bladder or liver biopsy. In the remaining two patients it
was discovered at autopsy. Family history of other types of
cancers was positive in 5 patients (22%), negative in 11
patients (48%) and unavailable in 7 (30%) patients. Pre-
senting symptoms included upper abdominal pain,
weight loss, nausea, vomiting, fever, painless jaundice,
hepatomegaly, upper abdominal mass, upper abdominal
tenderness, and gastrointestinal haemorrhage. Surgical
procedures and other therapies were reviewed and their
impact on survival noted. The survival of the patients dis-
charged from the hospital was determined using Kaplan
Meier analysis. P < 0.05 was considered significant. The
software used was PRISM, GraphPad Software San Diego,
California.
Results
Histological examination revealed 20 adenocarcinomas
(87%), 2 squamous cell carcinomas (9%) and one spindle
cell sarcoma (4%). At presentation, 14 (61%) gallbladder
cancers were stage IV, 5 (22%) were stage III and 4 (17%)
were stage II (Table 1, Table 2). Kaplan Meier analysis
revealed a mean survival of 3.2, 7.8 and 8.2 months for
stage IV, III, and II disease respectively (Figure 1). Only
one patient was alive (16.6 months with stage II disease)
at the time of analysis of this data. Out of 14 patients with
stage IV disease, six patients did not receive adjuvant
chemotherapy and survived for a mean period of 1.3
months. On the other hand, 8 patients who received adju-
vant multi-agent chemotherapeutic treatment survived for
a mean period of 4.6 months. This difference was statisti-
cally significant (p = 0.04).
Discussion
DeStoll described carcinoma of the gallbladder on the
bases of two autopsies in 1777 [2]. Since that time, pri-
mary carcinoma of the gallbladder has remained a uni-
formly fatal neoplasm. The reasons being (a) its late
presentation; (b) early spread by lymphatic; haematoge-
nous and direct route; (c) high propensity to seed the peri-
toneal surfaces after tumor spillage and (d) lack of
effective adjuvant therapy. The majority of reports suggest
that the gallbladder carcinoma is two to six times more
prevalent in women and the incidence peaks in the sev-
enth decade of life. In our series the female to male ratio
was approximately 4:1 and the mean age at the diagnosis
was 70.6 (range 42–85) years.
Despite advances in hepatobiliary imaging techniques
[3,4], the preoperative diagnosis of gallbladder carcinoma
remains a daunting task. This in part is related to the dis-
ease's non-specific presentation and its similarity to
benign biliary tract disorders. In our series the majority of
patients underwent ultrasound scan (USS) of the upper
abdomen (on the basis of their symptoms) which
revealed either the presence of gallstones with our without
thick walled gallbladder or liver metastases in advanced
cases. In those cases where the tumour was suspected, the
findings of contrast enhanced computerised tomography
(CE-CT) were not helpful either. The CE-CT findings
ranged from a mass in the right lobe of the liver, dilated
gallbladder, thick walled gallbladder, dilatation of intra-
hepatic bile ducts, abscess cavity in the right lobe of the
liver and liver metastases. Other studies have similarly
confirmed low sensitivity and specificity of USS and CE-
CT in achieving preoperative diagnosis of carcinoma of
the gallbladder [5-12]. The most common finding
described for gallbladder carcinoma on both USS and CE-
CT is diffuse thickening of the gallbladder. However this
is also commonly reported in the inflammatory condi-
tions of the gallbladder and therefore does not aid in the
diagnosis.
Table 1: American Joint Commission on Cancer (AJCC) Staging
TNM Definition Tumour Location
Tis Carcinoma in situ
T1a Gallbladder wall: mucosa
T1b Gallbladder wall: muscle
T2 Perimuscular connective tissue
T3 Serosa or one organ, liver <2 cm
T4 Two or more organs, liver >2 cm
N1 Hepatoduodenal ligament nodes
N2 Other regional lymph nodes
M0 No distant metastases
M1 Distant metastasesInternational Seminars in Surgical Oncology 2005, 2:6 http://www.issoonline.com/content/2/1/6
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In our series the majority of gallbladder carcinomas were
diagnosed either intra-operatively or subsequent to histo-
logical analysis following a cholecystectomy. In the era of
an laparoscopic cholecystectomy this situation poses a
major dilemma as laparoscopic technique has been asso-
ciated with an early and rapid dissemination of the dis-
ease both intraperitoneally and at the port site in patients
with proven gallbladder carcinomas and therefore pre-
cludes potentially curative resection [13-16]. It has there-
fore been suggested that laparoscopic surgery should not
be undertaken if radiological or clinical diagnosis of gall-
bladder carcinoma is suggested. Moreover, if such a diag-
nosis is suspected during initial laparoscopy then the
procedure should be abandoned to maximize the chance
of curative resection. As our experience ranged over the
twenty years period, only a handful of cholecystectomies
were performed laparoscopically and in all these patients
the diagnosis was revealed only after the histological anal-
ysis of the specimen.
The overall outcome of this disease is dismal with the 5-
year survival rate being less than 5% with a median sur-
vival of 5 to 8 months. Piehler and Circhlow [17]
reviewed 5836 patients with carcinoma of the gallbladder
from 1960 to 1978 and found an overall 5-year survival of
4.1% and one year survival of 11.8%. Only 25% were
resected for cure and of these only 16.5% survived 5 years.
However this figure dropped to 2.9% if the surgeon
Survival of patients according to the AJCC staging classification Figure 1
Survival of patients according to the AJCC staging classification.
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identified a tumour at the time of exploration. The best
survival was achieved in patients whose cholecystectomy
specimens were found to have incidental tumour. Even
then only 14.9% survived 5-year. Similarly Cubertafond
et al [18] reported a median survival of 3 months, a 5-year
survival of 5% and a 1-year survival of 14% amongst 724
carcinomas of the gallbladder. They observed no differ-
ences among the different surgical procedures adopted
and concluded that no progress had been made in the
treatment of gallbladder carcinoma. This clearly demon-
strates the minimal impact that surgical treatment has had
on this disease. However two recent reviews from Japan
have contradicted all these previous reports. Ogura et al
[19] have reported an impressive 50.7% 5 year survival for
984 patients undergoing radical resection compared to
only 6.2% for 702 patients undergoing conservative man-
agement. Similar Todoroki et al [20] have also shown that
radical resection for gallbladder carcinoma improves the
prognosis even for stage IV disease, provided that com-
plete gross tumour resection is combined with radiother-
apy. These results suggest the possible role of surgery ±
adjuvant therapy in changing the natural history of gall-
bladder carcinoma. In the current series none of the
patients underwent any extensive surgical resection either
because of incidental findings of gallbladder carcinoma
following a cholecystectomy or the tumour was too exten-
sive at the time of laparotomy. The longest survival
recorded was 18.7 months with a median survival of 5.1
months. Subset analysis revealed that patients with well
differentiated adenocarcinoma had the best outcome
although none of them survived even two years.
The stage at which the disease presents certainly has a
direct impact on the survival of the patient (Table 1, 2). A
number of authors have reported between 71% to 100%
5 year actuarial survival for stage I carcinoma both follow-
ing a simple and extended cholecystectomy [21,22],
between 22% to 100% for stage II carcinoma only follow-
ing an extended cholecystectomy [23,24], between 8% to
63% for stage III carcinoma [25,26] and between 8% to
25% for stage IV carcinoma following an extended resec-
tion ± adjuvant therapy [19,26]. We have not been able to
demonstrate such impressive survival figures in our
patients. The survival of our patients certainly was better
in the lower stage disease compared to the advanced stage
yet no patient even made it to 2 years (Figure 1). This may
be due to the fact that an extended cholecystectomy was
not performed in any of our patients. This validates the
point raised by Ogura et al [19] in their review that
extended therapy improves long term survival.
Adjuvant chemotherapy and/or radiotherapy for patients
with gallbladder cancer has not altered the dismal prog-
nosis, but may marginally improve survival. Chao et al
[27] reported no survival benefit between the two groups
of patients, one receiving and other denied adjuvant
chemotherapy and/or radiotherapy. On the other hand
Oswalt and Cruz [28] and Morrow et al [29] have shown
an improved median survival amongst the cohort of
patients receiving chemotherapy and/or radiotherapy fol-
lowing their surgery. Similarly Makela and Kairaluoma
[30] have demonstrated that superselective intra-arterial
chemotherapy with mitomycin for gallbladder cancer had
a 48% response rate and the responder had a significantly
better survival (34 months) compared to the non-
responders (8 months). However this type of therapy was
only effective in those patients whose tumours were con-
fined to gallbladder wall. Similarly in our study, patients
who received adjuvant multi-agent chemotherapeutic
treatment for stage IV disease had a significantly longer
mean survival period compared to the ones who did not
receive such treatment. This may simply reflect patient
selection bias and therefore it is impossible to credit min-
imal improvements in survival in ours and other series to
chemotherapy alone without a large randomised trial. An
important point to make is that none of the patients who
received chemotherapy in our series survived beyond two
years – indeed a disappointing outcome.
Table 2: Staging of gallbladder carcinoma
Stage TNM Modified Nevin
0 Tis N0 M0 In situ carcinoma
I T1 N0 M0 In situ carcinoma
II T2 N0 M0 Mucosal or muscular invasion
III T1 N1 M0
T2 N1 M0
T3 N0 M0
T3 N1 M0
Transmural direct liver invasion
IV A T4 N0 M0
T4 N1 M0
Lymph node metastasis
IV B Any T N2 M0
Any T Any N M1
Lymph node metastasis ± distant metastasisPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
International Seminars in Surgical Oncology 2005, 2:6 http://www.issoonline.com/content/2/1/6
Page 5 of 5
(page number not for citation purposes)
Conclusion
Gallbladder carcinoma not only presents a diagnostic
dilemma but also poses a difficult treatment option in the
era of laparoscopic cholecystectomy. The majority of
patients with gallbladder cancer present with advanced
stage disease (stage IV) which carries a dismal prognosis.
Chemotherapy seems to have some survival benefit in
stage IV disease, but no randomized controlled trials exit
to define its role in the adjuvant setting. The prognosis of
this disease is dismal and even a 2 year survival seems to
be the exception rather than the rule.
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